Agios Pharm
USUSDAgios Pharm (LSE:0HB0) — Biotechnology: Pharmaceutical Preparations. Кількість бірж, де торгуються акції компанії: 2. На сторінці — ціна й графік, дивіденди, найбільші власники та історія кількості акцій.
Про компанію
- Сайт
- agios.com
- Для інвесторів
- investor.agios.com/
- Сектор
- Health Care · Biotechnology: Pharmaceutical Preparations
- Штаб-квартира
- Cambridge, United States
- Керівник
- Brian M. Goff
- Працівників
- 539
- Заснована
- 2008
- Акцій в обігу
- 59.7 млн на 2026-07-24
- Вільний обіг
- 50.02 млн
- Капіталізація
- 2 млрд USD
- Інсайдери
- 1.07%
- Інституції
- 112.31%
- Галузь (SIC)
- Pharmaceutical Preparations
- ISIN
- US00847X1046
- LEI
- 529900ONJHY8EOGYT555
- FCF
- −365 млн USD
- Борг
- 0
- Прибуток і FCF — за 12 місяців до 30.06.2026 (останній звіт компанії).
Опис
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Найбільші власники
| Власник | Частка | Акцій | Дата звіту |
|---|---|---|---|
| Blackrock Inc. | 10.81% | 6.46 млн | 2026-06-30 |
| Farallon Capital Managem… | 9.91% | 5.92 млн | 2026-06-30 |
| State Street Corporation | 5.92% | 3.53 млн | 2026-06-30 |
| Lynx1 Capital Management… | 5.71% | 3.41 млн | 2026-06-30 |
| Shaw D.E. & Co., Inc. | 5.2% | 3.11 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.85% | 2.9 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4.49% | 2.68 млн | 2026-06-30 |
| Armistice Capital, LLC | 4.02% | 2.4 млн | 2026-06-30 |
| Erste Asset Management G… | 3.61% | 2.15 млн | 2026-06-30 |
| SPDR SERIES TRUST-State… | 3.54% | 2.11 млн | 2026-08-31 |
| Nomura Asset Management… | 3.54% | 2.11 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.16% | 1.89 млн | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.52% | 1.51 млн | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 2.28% | 1.36 млн | 2026-06-30 |
| Delaware Group Equity Fu… | 1.92% | 1.14 млн | 2026-05-31 |
| VANGUARD INDEX FUNDS-Van… | 1.32% | 788 655 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 683 990 | 2026-06-30 |
| Fidelity Salem Street Tr… | 1.08% | 646 318 | 2026-07-31 |
| Fidelity Rutland Square… | 0.88% | 526 121 | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.86% | 511 994 | 2026-07-31 |
| FOUSE JACQUALYN A. (Dire… | ≈0.26% | 154 156 | 2026-06-18 |
| GHEUENS SARAH (Officer) | ≈0.09% | 54 645 | 2026-08-04 |
| SCADDEN DAVID T. (Direct… | ≈0.03% | 20 419 | 2026-06-18 |
| HO MAYKIN (Director) | ≈0.03% | 19 848 | 2026-06-18 |
| BALLAL RAHUL D. (Directo… | ≈0.03% | 15 230 | 2026-06-18 |
| SMITH CYNTHIA (Director) | ≈0.03% | 15 230 | 2026-06-18 |
| FOSTER-CHEEK KAYE I (Dir… | ≈0.02% | 12 484 | 2026-06-18 |
| ADAMS CATHERINE OWEN (Di… | ≈0.02% | 10 865 | 2026-06-18 |
| CAPELLO JEFFREY D (Direc… | ≈0.02% | 10 865 | 2026-06-18 |
| BACKSTROM JAY T (Directo… | ≈0% | 1 447 | 2026-07-08 |
